Oxitec Ltd.

Oxitec Ltd. specializes in innovative biological solutions for controlling pest populations that threaten public health and agriculture. The company focuses on genetically modified organisms to combat disease-carrying mosquitoes and crop-damaging pests. Founded in 2002, Oxitec Ltd.

is headquartered in Abingdon, UK, and is known for its development of genetically modified organisms aimed at controlling pest populations. The company has undergone strategic pivots to enhance its focus on public health, particularly in combating diseases transmitted by mosquitoes. The CEO team includes Grey Frandsen, Hadyn Parry, and Stephan Gerth. Oxitec has successfully raised a total of USD 6.

20 mn through various funding rounds, with the most recent being a GRANT of USD 18. 00 mn from the Bill & Melinda Gates Foundation on April 13, 2022. Oxitec has completed 8 deals to date. Oxitec develops innovative biological solutions aimed at controlling pest populations that threaten public health and agricultural productivity.

The company's core offerings include the Friendly™ platform, which employs genetically modified organisms to reduce populations of disease-carrying mosquitoes such as Aedes aegypti, responsible for transmitting dengue, Zika, and chikungunya viruses. Additionally, Oxitec is expanding its efforts to target malaria-carrying mosquitoes, enhancing its public health initiatives across multiple continents including Africa, North America, and South America. In the agricultural sector, Oxitec's technology is applied against various crop-damaging pests, utilizing its Friendly™ platform to mitigate challenges posed by agricultural threats globally. The company's customer base includes governmental health agencies, agricultural organizations, and environmental groups, all of which seek effective solutions to combat public health crises and enhance food security.

In 2019, Oxitec reported a revenue of USD 4,062,774. 80 and an EBITDA of -USD 3,253,029. 70. The company’s revenue model is structured around partnerships and collaborations with public health agencies and agricultural stakeholders, focusing on impact-driven solutions for pest control.

Transactions typically involve contractual agreements with government entities and non-governmental organizations, facilitating the deployment of their genetically modified products in targeted regions. This includes arrangements for project-based funding, where clients engage Oxitec for specific public health or agricultural initiatives, leveraging the company’s proprietary technologies. Pricing structures for Oxitec’s services are determined based on project scope and client needs, encompassing comprehensive service agreements that integrate their Friendly™ mosquito and agricultural pest control solutions. The company’s flagship offerings, including the Friendly™ Aedes Program and agricultural pest solutions, are central to its revenue generation strategy, fostering sustainable partnerships that align with its mission to address pressing global challenges.

Oxitec plans to utilize the recent GRANT funding of USD 18. 00 mn from the Bill & Melinda Gates Foundation to advance its anti-malaria program. This funding will support the development of new products aimed at reducing malaria-carrying mosquito populations. Additionally, the company is looking to expand its operations into new geographic regions, particularly targeting areas in Africa and South America by the end of 2023, enhancing its public health initiatives to combat mosquito-borne diseases.